Research article

BACH1 Ser919Pro variant and breast cancer risk

Pia Vahteristo^1,2 , Kristiina Yliannala¹ , Anitta Tamminen¹ , Hannaleena Eerola^1,3 , Carl Blomqvist^3,4 and Heli Nevanlinna¹

¹  Departments of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland

²  Department of Medical Genetics, University of Helsinki, Helsinki, Finland

³  Departments of Oncology, Helsinki University Central Hospital, Helsinki, Finland

⁴  Department of Oncology, Uppsala University Hospital, Uppsala, Sweden

author email corresponding author email

BMC Cancer 2006, 6:19doi:10.1186/1471-2407-6-19

Published:	24 January 2006

Abstract

Background

BACH1 (BRCA1-associated C-terminal helicase 1; also known as BRCA1-interacting protein 1, BRIP1) is a helicase protein that interacts in vivo with BRCA1, the protein product of one of the major genes for hereditary predisposition to breast cancer. Previously, two BACH1 germ line missense mutations have been identified in early-onset breast cancer patients with and without family history of breast and ovarian cancer.

In this study, we aimed to evaluate whether there are BACH1 genetic variants that contribute to breast cancer risk in Finland.

Methods

The BACH1 gene was screened for germ line alterations among probands from 43 Finnish BRCA1/2 negative breast cancer families. Recently, one of the observed common variants, Ser-allele of the Ser919Pro polymorphism, was suggested to associate with an increased breast cancer risk, and was here evaluated in an independent, large series of 888 unselected breast cancer patients and in 736 healthy controls.

Results

Six BACH1 germ line alterations were observed in the mutation analysis, but none of these were found to associate with the cancer phenotype. The Val193Ile variant that was seen in only one family was further screened in an independent series of 346 familial breast cancer cases and 183 healthy controls, but no additional carriers were observed. Individuals with the BACH1 Ser919-allele were not found to have an increased breast cancer risk when the Pro/Ser heterozygotes (OR 0.90; 95% CI 0.70–1.16; p = 0.427) or Ser/Ser homozygotes (OR 1.02; 95% CI 0.76–1.35; p = 0.91) were compared to Pro/Pro homozygotes, and there was no association of the variant with any breast tumor characteristics, age at cancer diagnosis, family history of cancer, or survival.

Conclusion

Our results suggest that the BACH1 Ser919 is not a breast cancer predisposition allele in the Finnish study population. Together with previous studies, our results also indicate that although some rare germ line variants in BACH1 may contribute to breast cancer development, the contribution of BACH1 germline alterations to familial breast cancer seems marginal.